Archives

CX-2029, a PROBODY Drug Conjugate Targeting CD71 (Transferrin Receptor): Results From a First-in-Human study (PROCLAIM-CX-2029) in Patients With Advanced Cancer

Melissa Johnson, Anthony El-Khoueiry, Navid Hafez, Nehal Lakhani, Hirva Mamdani, Jordi Rodon, Rachel E. Sanborn, Thang Ho, Rachel Li, Jana Waldes, Alexander I. Spira. Oral presentation at the ASCO20 Virtual Scientific Program, May 29-31, 2020.

Learn More

Preclinical Development of a Probody™ Drug Conjugate (PDC) Targeting CD71 for the Treatment of Multiple Cancers

Shweta Singh, Amy DuPage, Annie Yang Weaver, Michael Krimm, Clayton White, Jason Sagert ,Yuanhui Huang, Linnea Diep, Shouchun Liu, Jennifer Richardson, W. Michael Kavanaugh, Jonathan A. Terrett, Luc R. Desnoyers. Poster presented at AACR 2016, April 16-20, New Orleans, Louisiana.

Learn More

Developing a CD71-Targeting Probody™ Drug Conjugate (PDC) for Activity in Multiple Solid Tumor and Lymphoma Models and for Tolerability in Non-human Primates

Shweta Singh, Laura Serwer, Niharika Chauhan, Amy DuPage, Michael Krimm, Ken Wong, Yuanhui Huang, Andrew Jang, Eric Ureno, Adam Miller, Sarah Patrick, Shanti Duvur, Fritz Buchanan, Matthew Ravn, Rob Leanna, Ilaria Badagnani, Tracy Henriques, Shouchun Liu, Luc Desnoyers, Claus Krebber, Sridhar Viswanathan, Jennifer Richardson, Susan Morgan-Lappe and W. Michael Kavanaugh. Poster presented at AACR-NCI-EORTC International Conference on Molecular Targets 2017, October 26-30, Philadelphia, Pennsylvania.

Learn More

A Multi-Analyte HPLC-MS/MS Approach to Assessing Exposure of a Probody™ Drug Conjugate in Preclinical Studies

Laura P. Serwer, Shweta Singh, Claus Krebber, Shouchun Liu, Niharika Chauhan, Robert Leanna, Hong Lu, Ilaria Badagnani, Tracy Henriques, Susan Morgan-Lappe, William Mylott Jr., Sridhar Viswanathan, Jennifer H. Richardson, W. Michael Kavanaugh. Poster presented at AACR-NCI-EORTC International Conference on Molecular Targets 2017, October 26-30, Philadelphia, Pennsylvania.

Learn More